StarTric

StarTric TriClover technology, for the transcatheter repair of the Tricuspid Valve, has successfully finalised its first phase of pre-clinical testing, aimed at evaluating safety and functionality of our innovative triple edge-to-edge repair concept. For all those interested, the main results of this in vivo chronic and ex vivo evaluation have been published by the the American College of Cardiology JACC Journals. Encouraged by these promising results, we’re now advancing the development of our Investigational Device for comprehensive clinical validation. A heartfelt thank you to the authors of this important publication and to everyone contributing to StarTric’s mission of redefining tricuspid regurgitation care.

As we approach the end of 2024, we at StarTric reflect on a great year of growth, collaboration, and progress in advancing our TriClover technology towards clinical application. We extend our heartfelt thanks to all who have supported and contributed to our journey. 💫 A special thanks to the new members of our Scientific Advisory Board, Prof. Maurizio Taramasso and Dr. Azeem Latib, for joining forces with Prof. Ottavio Alfieri and Prof. Michele De Bonis to shape our clinical strategy. 💫 To the incredible team at NLC Health Ventures, with a special mention to Alessandro Radaelli and Ellis Aune, your support has been transformative, empowering us far beyond financial backing. 💫 Gratitude also goes to everyone who helped introduce TriClover and our pre-clinical results to the global interventional cardiology community. As Dr. Guido Ascione —whether presenting at EuroPCR and TCT or as Shark Tank finalists. 💫 An appreciation to our technology partners—GARD CONSULTING, LifeTec Group™ , Veranex, to mention only a few—your expertise fuels our innovation. 💫 And to our investors whose confidence drives us forward: thank you for believing in our mission. As we look ahead, we are inspired by the vision of delivering a new, effective therapy for tricuspid regurgitation. Wishing everyone a successful and fulfilling year ahead! 🚀

Last week, NLC hosted the Cardiovascular Venture Day, and it was a fantastic showcase of innovation, collaboration, and impactful ideas. A big thank you to Sjaak Deckers for delivering an inspiring keynote to kick off the day! Event Highlights: ✅ 30+ participants from across our ecosystem, including investors, medtech experts, and strategic partners. ✅7 presentations from our portfolio ventures: StarTric, Kaminari Medical, Haermonics, HapticHeart Solutions, Sigilla, ProVascTec, and Nilocas. ✅ Presentation from Meike Bomhof, Avania, Reimbursement Expert, providing critical insights into navigating market access strategies. 💡 The day was filled with rich discussions, actionable feedback, and valuable connections, thanks to our knowledgeable and supportive audience. We were delighted to welcome representatives from Gilde Healthcare, EQT Group, Brightlands Venture Partners, Brabantse Ontwikkelings Maatschappij (BOM), Invest-NL, Demcon, XGEN Venture, LifeTec Group™ , SUAZIO, Wolfnose Medtech Advisors. Your presence made this event truly impactful! 🚀 A heartfelt thank you to everyone who joined and contributed to the success of this event. Together, we’re building a brighter future for healthcare innovation! #innovation #cardiovascular #impact #healthcare

We are thrilled to announce that StarTric has been invited to present its TriClover technology, for transcatheter repair of the tricuspid valve, at the prestigious Shark Tank Innovation competition, during the CRF TCT event that will go live in just a few days in Washington D.C. StarTric presentation, A Novel Transcatheter Technique to Repair the Tricuspid Valve, will be delivered on Sunday the 27th by our DANIELE ZANOTTI. StarTric is one of the six only finalists, selected among the most promising new technologies of the whole structural heart landscape. This invitation to the #TCT2024 Shark Tank, that adds to the others to present TriClover at two different scientific sessions of next TCT, confirms a deep interest and curiosity among key-opinion-leaders and innovation experts in interventional cardiology. We are more than proud of this recognition and totally committed to make of StarTric's TriClover a new therapeutic reality. Stay tuned and looking forward to see you in Washington D.C.! 🦈

StarTric will attend #TCT2024 in Washington D.C from this October 27th. 🌟 We are very proud for having been invited to present our transcatheter tricuspid repair technology, TriClover, from the prestigious podium of the #TCT2024. - On Monday the 28th we will present the moderated abstract: “TriClover: A Novel Transcatheter Technique to Repair the Tricuspid Valve With High Potential for Effectiveness and Wide Indications to Treat Tricuspid Regurgitation”, during the session of Tricuspid Repair Studies 1, Station 7, in the Innovation & Exhibit Hall. - On Tuesday the 29th, we will present “A Novel Transcatheter Technique to Repair the Tricuspid Valve (StarTric): Technology Description and Experimental Insights”, during the session TCT Innovation 12, Innovations in Transcatheter Tricuspid Valve Repair Technologies. The TCT will be a great opportunity to show our encouraging first in vivo chronic results to the international scientific community of interventional cardiology. Most of our team will be at the #TCT2024, open to exchange there on the future of #tricuspid valve therapies. See you in Washington! ☘

Incredible experience attending the LSI Europe 24 Conference in Lisbon. ✨ A great opportunity for our Eugenio Passanante to present StarTric progresses and vision to make available a truly effective, safe and easy solution to treat millions of patients suffering from #Tricuspid Regurgitation. Many thanks to #LSIEurope224 for such a powerful platform to engage with medtech professionals, investors, and attend insightful panels on latest industry trends. Looking forward to staying in touch. Exciting times ahead! 🚀

StarTric is very proud to announce the appointment of Dr Azeem Latib as member of its Scientific Advisory Board, teaming up with Ottavio Alfieri, Michele De Bonis and Maurizio Taramasso. Azeem brings to our project his stellar reputation as scientist and physician, and his deep expertise in new structural heart technologies.   Azeem’s experience and advice will be of extreme value in steering the clinical validation path of StarTric's Transcatheter Edge-to-Edge Repair (TEER) technology for the tricuspid valve, all the way from strategic design to successful execution in both Europe and the US.   “I'm very excited about the potential of this novel transcatheter tricuspid technology that is based on an established surgical technique and addresses an unmet clinical in patients with severe TR" Azeem said.   Grateful of his words, we warmly welcome Azeem to the StartTric SAB, so to purse with a shared vision the goal of providing a technology to effectively and safely treat Tricuspid Regurgitation, to millions of patients in need. 

☘ We are excited to announce that StarTric has been selected to participate to LSI Europe 2024 in Lisbon this September 16-20th. Our Eugenio Passanante will be presenting our unique transcatheter repair technology and share insights into our recent advancements and plans for the future. Feel free to connect with him during the event. Looking forward to seeing you there!

Maurizio Taramasso joins the Scientific Advisory Board (SAB) of StarTric! We are really proud to announce that Maurizio Taramasso, (HerzZentrum Hirslanden Zurich, Clinic Hirslanden) is now member of our SAB, chaired by Ottavio Alfieri and coordinated by Michel De Bonis. Maurizio brings to the project a wealth of expertise in interventional cardiology, in particular in tricuspid valve therapies. Besides, he can contribute with his deep knowledge of new technologies and of their clinical validation, an energizing team spirit, acute thinking and a bright reputation for independent judgement. “I am really excited to start this journey, having the strong convintion that the StarTric technology will help many patients suffering from severe tricuspid regurgitation to improve theis quality of life, even in challenging valve anatomy ” Maurizio said. Maurizio has already started to participate as investigator to pre-clinical validation sessions of the StarTric technology, in view of assuming a key role during the clinical validation trials, which will shortly follow the current development of the investigational device. Welcome Maurizio to our growing Team!

We are thrilled to announce that StarTric has successfully secured a new seed financing round, fueling the development of our groundbreaking technology for #transcatheter #tricuspid valve repair. This milestone wouldn’t be possible without the unwavering support of our founders and our investors including NLC Health Ventures, Growth Engine, NLC Health Impact Fund, and several Business Angels. #Tricuspid Regurgitation (TR) is a severe cardiac condition that affects millions of patients globally, many of whom still lack effective and accessible therapeutic options. At StarTric, we are dedicated to fill this critical gap and improve the lives of those impacted by TR. A heartfelt thank you to our clinical partners, investors and supporters for believing in our vision. Together, we are revolutionizing cardiac care. Stay tuned for more exciting updates on our journey! ☘ 🚀